CSL logo

CSL

CSLLY | OTC
Chart Builder DCF Calculator
$34.00
-$0.41 (-1.19%)
At close: Nov 16, 2026, 3:59 PM ET
$34.00
$0.00 (0.00%)
After-hours: Nov 16, 2026, 3:59 PM ET
-1.19%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
42
Fundamentals Average
Market Sentiment Neutral
Moat Wide
Sector Rank #470/1021 (Top 46%)

Why Price Moved

2 months ago
+2.66%

Shares are trading higher after tapping Amazon's c...

Key Statistics

Market Data

Market Cap $65.13B
1D Range
33.28 34.31
52W Range
16.35 35.39

Valuation (TTM)

PE -25.66
PB 4.40
EV/EBITDA 14.70

Valuation (NTM)

Forward PE 22.06
Forward PEG 4,167.41
Price Target $153.50
Loading financial charts...

Profile

CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare product...

Sector Healthcare
Industry Biotechnology
Employees 29,000
IPO Date Dec 29, 2009
Website www.csl.com
Fiscal Year July - June

Latest News

BROAD ARROW'S ZÜRICH AUCTION CONCLUDES A REMARKABLE 2026 AUCTION CALENDAR

7 days ago · globenewswire.com

BROAD ARROW'S ZÜRICH AUCTION CONCLUDES A REMARKABLE 2026 AUCTION CALENDAR
CSL Limited (CSLLY) Shareholder/Analyst Call Transcript

21 days ago · seekingalpha.com

CSL Limited (CSLLY) Shareholder/Analyst Call Transcript
CSL appoints Deborah Waterhouse as CEO & Managing Director

27 days ago · prnewswire.com

CSL appoints Deborah Waterhouse as CEO & Managing Director
Australia's CSL appoints Deborah Waterhouse as CEO

27 days ago · reuters.com

Australia's CSL appoints Deborah Waterhouse as CEO
HRMY vs. CSLLY: Which Stock Is the Better Value Option?

1 month ago · zacks.com

HRMY vs. CSLLY: Which Stock Is the Better Value Option?
CSL y Alentis desarrollarán y comercializarán lixudebart para enfermedades renales y hepáticas raras

1 month ago · prnewswire.com

CSL y Alentis desarrollarán y comercializarán lixudebart para enfermedades renales y hepáticas raras
CSL strikes US$1.6 billion licensing deal for rare disease drug

1 month ago · proactiveinvestors.com

CSL strikes US$1.6 billion licensing deal for rare disease drug
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

1 month ago · reuters.com

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

1 month ago · prnewswire.com

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
Australia's CSL taps Amazon's cloud unit to boost research pipeline

2 months ago · reuters.com

Australia's CSL taps Amazon's cloud unit to boost research pipeline

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.